Một Thước Đo Cơ Bắp Hệ Xương Mới Trước Phẫu Thuật Là Dự Đo Có Thể Dự Đo Các Biến Chứng Sau Phẫu Thuật, Tồn Tại Dài Hạn Và Tái Phát Khối U Ở Bệnh Nhân Ung Thư Dạ Dày Sau Phẫu Thuật Cắt Dạ Dày Cấp Độ

Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;5:277–300. Papenfuss WA, Kukar M, Oxenberg J, et al. Morbidity and mortality associated with gastrectomy for gastric cancer. Ann Surg Oncol. 2014; 9:3008–14. Hartgrink HH, Jansen EP, van Grieken NC, van de Velde CJ. Gastric cancer. Lancet. 2009;9688:477–90. Prado CM, Lieffers JR, McCargar LJ, et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol. 2008;7:629–35. Reisinger KW, van Vugt JL, Tegels JJ, et al. Functional compromise reflected by sarcopenia, frailty, and nutritional depletion predicts adverse postoperative outcome after colorectal cancer surgery. Ann Surg. 2015; 2:345–52. Zheng ZF, Lu J, Zheng CH, et al. A novel prognostic scoring system based on preoperative sarcopenia predicts the long-term outcome for patients after R0 resection for gastric cancer: experiences of a high-volume center. Ann Surg Oncol. 2017; 24:1795. Tan BH, Birdsell LA, Martin L, Baracos VE, Fearon KC. Sarcopenia in an overweight or obese patient is an adverse prognostic factor in pancreatic cancer. Clin Cancer Res. 2009;22:6973–79. Voron T, Tselikas L, Pietrasz D, et al. Sarcopenia impacts on short- and long-term results of hepatectomy for hepatocellular carcinoma. Ann Surg. 2015;6:1173–83. Lieffers JR, Bathe OF, Fassbender K, Winget M, Baracos VE. Sarcopenia is associated with postoperative infection and delayed recovery from colorectal cancer resection surgery. Br J Cancer. 2012;6:931–36. Wagner D, Buttner S, Kim Y, et al. Clinical and morphometric parameters of frailty for prediction of mortality following hepatopancreaticobiliary surgery in the elderly. Br J Surg. 2016;2:e83–92. Buettner S, Wagner D, Kim Y, et al. Inclusion of sarcopenia outperforms the modified frailty index in predicting 1-year mortality among 1326 patients undergoing gastrointestinal surgery for a malignant indication. J Am Coll Surg. 2016;4:397–407. Joglekar S, Asghar A, Mott SL, et al. Sarcopenia is an independent predictor of complications following pancreatectomy for adenocarcinoma. J Surg Oncol. 2015;6:771–75. Margadant CC, Bruns ER, Sloothaak DA, et al. Lower muscle density is associated with major postoperative complications in older patients after surgery for colorectal cancer. Eur J Surg Oncol. 2016;11:1654–59. Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2010 (version 3). Gastric Cancer. 2011;2:113–23. Sobin LH, Gospodarowicz M, Wittekind C. International union against cancer, TNM classification of malignant tumors. 7th ed. Wiley: New York; 2010. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;2:205–13. Bang YJ, Kim YW, Yang HK, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after d2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 2012;9813:315–21. Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;18:1810–20. Aubrey J, Esfandiari N, Baracos VE, et al. Measurement of skeletal muscle radiation attenuation and basis of its biological variation. Acta Physiol Oxford. 2014;3:489–97. Goodpaster BH, Kelley DE, Thaete FL, He J, Ross R. Skeletal muscle attenuation determined by computed tomography is associated with skeletal muscle lipid content. J Appl Physiol 1985. 2000;1:104–10. Dodson RM, Firoozmand A, Hyder O, et al. Impact of sarcopenia on outcomes following intra-arterial therapy of hepatic malignancies. J Gastrointest Surg. 2013;12:2123–32. Weinberg M, SSDA. Characterization of skeletal muscle and body mass indices in younger and older women with stage II and III breast cancer. J Am Geriatr Soc. 2016;supplement:S86. McSorley ST, Black DH, Horgan PG, McMillan DC. The relationship between tumour stage, systemic inflammation, body composition and survival in patients with colorectal cancer. Clin Nutr. 2017. https://doi.org/10.1016/j.clnu.2017.05.017. Fang HY, Yang H, He ZS, et al. Log odds of positive lymph nodes is superior to the number- and ratio-based lymph node classification systems for colorectal cancer patients undergoing curative (R0) resection. Mol Clin Oncol. 2017;5:782–88. Sun Z, Wang ZN, Zhu Z, et al. Evaluation of the Seventh Edition of American Joint Committee on Cancer TNM Staging System for Gastric Cancer: results from a Chinese monoinstitutional study. Ann Surg Oncol. 2012;6:1918–27. Cheng C, Wang R, Li Y, et al. EGFR Exon 18 mutations in East Asian Patients with lung adenocarcinomas: a comprehensive investigation of prevalence, clinicopathologic characteristics, and prognosis. Sci Rep. 2015. https://doi.org/10.1038/srep13959. Sukumar S, Roghmann F, Trinh VQ, et al. National trends in hospital-acquired preventable adverse events after major cancer surgery in the USA. Bmj Open. 2013;3:e002843. Schneider EB, Hyder O, Brooke BS, et al. Patient readmission and mortality after colorectal surgery for colon cancer: impact of length of stay relative to other clinical factors. J Am Coll Surg. 2012;4:390–8; 398–99. Ghaferi AA, Dimick JB. Variation in mortality after high-risk cancer surgery: failure to rescue. Surg Oncol Clin N Am. 2012;3:389–95. Rosenberg IH. Sarcopenia: origins and clinical relevance. J Nutr. 1997;5(Suppl):990S–1S. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et al. Sarcopenia: European consensus on definition and diagnosis: report of the European Working Group on sarcopenia in older people. Age Ageing. 2010;4:412–23. Fielding RA, Vellas B, Evans WJ, et al. Sarcopenia: an undiagnosed condition in older adults: current consensus definition: prevalence, etiology, and consequences. International Working Group on Sarcopenia. J Am Med Dir Assoc. 2011;4:249–56. Okumura S, Kaido T, Hamaguchi Y, et al. Impact of preoperative quality as well as quantity of skeletal muscle on survival after resection of pancreatic cancer. Surgery. 2015;6:1088–98. Okumura S, Kaido T, Hamaguchi Y, et al. Impact of the preoperative quantity and quality of skeletal muscle on outcomes after resection of extrahepatic biliary malignancies. Surgery. 2016;3:821–33. Zoico E, Corzato F, Bambace C, et al. Myosteatosis and myofibrosis: relationship with aging, inflammation and insulin resistance. Arch Gerontol Geriatr. 2013;3:411–16. Shachar SS, Deal AM, Weinberg M, et al. Skeletal muscle measures as predictors of toxicity, hospitalization, and survival in patients with metastatic breast cancer receiving taxane-based chemotherapy. Clin Cancer Res. 2017;3:658–65. Kanda M, Tanaka C, Kobayashi D, et al. Proposal of the coagulation score as a predictor for short-term and long-term outcomes of patients with resectable gastric cancer. Ann Surg Oncol. 2017;2:502–09. Argiles JM, Busquets S, Stemmler B, Lopez-Soriano FJ. Cachexia and sarcopenia: mechanisms and potential targets for intervention. Curr Opin Pharmacol. 2015;22:100–06. Dodson S, Baracos VE, Jatoi A, et al. Muscle wasting in cancer cachexia: clinical implications, diagnosis, and emerging treatment strategies. Annu Rev Med. 2011;62:265–79. Pedersen BK, Febbraio MA. Muscles, exercise, and obesity: skeletal muscle as a secretory organ. Nat Rev Endocrinol. 2012;8:457–65. Lazaro JB, Kitzmann M, Poul MA, Vandromme M, Lamb NJ, Fernandez A. Cyclin dependent kinase 5, Cdk5, is a positive regulator of myogenesis in mouse C2 cells. J Cell Sci. 1997;110:1251–60. Cao L, Zhou J, Zhang J, et al. Cyclin-dependent kinase 5 decreases in gastric cancer and its nuclear accumulation suppresses gastric tumorigenesis. Clin Cancer Res. 2015;6:1419–28. Maddocks M, Murton AJ, Wilcock A. Improving muscle mass and function in cachexia: non-drug approaches. Curr Opin Support Palliat Care. 2011;4:361–64. Argiles JM, Busquets S, Lopez-Soriano FJ, Costelli P, Penna F. Are there any benefits of exercise training in cancer cachexia? J Cachexia Sarcopenia Muscle. 2012;2:73–76. Di Girolamo FG, Situlin R, Mazzucco S, Valentini R, Toigo G, Biolo G. Omega-3 fatty acids and protein metabolism: enhancement of anabolic interventions for sarcopenia. Curr Opin Clin Nutr Metab Care. 2014;2:145–50. Dallmann R, Weyermann P, Anklin C, et al. The orally active melanocortin-4 receptor antagonist BL-6020/979: a promising candidate for the treatment of cancer cachexia. J Cachexia Sarcopenia Muscle. 2011;3:163–74. Grossmann M. Myostatin inhibition: a new treatment for androgen deprivation-induced sarcopenia? J Clin Endocrinol Metab. 2014;10:3625–28. Berardi E, Annibali D, Cassano M, Crippa S, Sampaolesi M. Molecular and cell-based therapies for muscle degenerations: a road under construction. Front Physiol. 2014;5:119. Kung T, Springer J, Doehner W, Anker SD, von Haehling S. Novel treatment approaches to cachexia and sarcopenia: highlights from the 5th Cachexia Conference. Expert Opin Investig Drugs. 2010;4:579–85.